Developer docs
API playgroundTry for free, no card

Search company profiles

AsymBio

Full company profile

uuid00sn7h4

Namestring
AsymBio
Legal namestring
凯莱英生物技术有限公司
Websiteurl
asymbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

AsymBio (凯莱英生物技术有限公司) is a biopharmaceutical contract development and manufacturing organization (CDMO) and wholly-owned subsidiary of Asymchem Group (002821.SZ / 6821.HK), founded in January 2019. The company provides end-to-end CDMO services across the full biopharmaceutical development lifecycle for global pharmaceutical and biotech clients, spanning early-stage research, process development, toxicology and clinical batches, and commercial-scale manufacturing for biologics including monoclonal antibodies, bispecific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), novel drug conjugates (RDCs, AOCs, PDCs, APCs, bispecific ADCs, dual-payload ADCs), and mRNA therapeutics.

The company's core technology consists of seven integrated platforms: the proprietary AmigoCHO Cell Line Development Platform achieving 8 g/L expression levels in 7 weeks; Upstream and Downstream Process Development Platforms with upstream timelines shortened to 9 weeks; the Conjugation Toolbox supporting multiple conjugation modalities (cysteine, lysine, engineered cysteine, interchain bridging, enzymatic via mTG/sortase, and glyco-remodeling via GlycoConnect, GlycoT, DisacLink, iGDC); the IMPACT Drug Product Development Platform; the Payload-Linker CMC Development Platform supporting 70+ IND and 13 NDA projects; and a Comprehensive Analytical Platform integrating physicochemical, mass spectrometry, and bioassay capabilities. Operations are conducted across a Shanghai "Golden Triangle" network: the Zhangjiang Center of Biological Technology and Innovation (CBTI), the Jinshan manufacturing site, and the 130,000+ square meter Fengxian Commercial Production Base (66,000L bioreactor capacity, 2 million vial annual capacity), with a US business development office in Woburn, MA. Facilities are compliant with NMPA, FDA, and EMA standards.

AsymBio operates a project-based B2B contract services revenue model with pricing specific to each engagement. Go-to-market is event-driven enterprise field sales, with active participation in major industry conferences (World ADC, BIOCHINA, Festival of Biologics, ADC Asia Congress) and direct engagement through a business development team. Customer concentration is horizontal across pharmaceutical and biotech companies globally, with the company leveraging the Asymchem Group ecosystem including Tianjin's payload-linker manufacturing capabilities for integrated supply chain advantages.

Short descriptiontext

AsymBio is a biopharmaceutical CDMO and subsidiary of Asymchem Group providing end-to-end biologics development and manufacturing services (antibodies, recombinant proteins, ADCs, novel drug conjugates, mRNA) for global pharma and biotech clients across a Shanghai-based three-facility manufacturing network compliant with NMPA, FDA, and EMA standards.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics CDMO services, antibody manufacturing, drug conjugate development, recombinant protein production, biopharmaceutical contract manufacturing
Industry4 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biologics Contract Development and Manufacturing (CDMO) Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical CDMO Services
TypeProfessional Services
Description

Full-service contract development and manufacturing organization providing one-stop CDMO solutions for biologics including antibodies, recombinant proteins, and novel drug conjugates. Services span early-stage research, process development, toxicology batches, clinical batches, and commercial-scale manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies.

asymbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AsymBio provides one-stop biologics contract development and manufacturing organization (CDMO) services for global pharmaceutical and biotech companies, spanning the full biopharmaceutical lifecycle from cell line development, upstream and downstream process development, conjugation, drug product development, and analytical services through to clinical and commercial-scale manufacturing for antibodies, recombinant proteins, novel drug conjugates (ADCs, RDCs, AOCs, PDCs, BsADCs), and mRNA products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • IND-enabling conjugation process development can be completed in 2-3 months
+5 more records
Product overview1 text field

AsymBio is a technology-driven biologics CDMO and subsidiary of Asymchem Group providing integrated one-stop CDMO services spanning the full biopharmaceutical development lifecycle. The company operates seven integrated technology platforms: AmigoCHO Cell Line Development Platform for high-titer clone development; Upstream and Downstream Process Development Platforms for IND-enabling workflows; Conjugation Toolbox for ADC and bioconjugate process development supporting random and site-specific conjugation technologies; IMPACT Drug Product Development Platform for formulation solutions; Payload-Linker CMC Development Platform supporting 70+ IND and 13 NDA projects; and Comprehensive Analytical Platform for physicochemical, mass spectrometry, and bioassay characterization. The company provides end-to-end services from early-stage research through commercial-scale manufacturing across antibodies, ADCs, novel drug conjugates (RDCs, AOCs, PDCs, APCs, BsADCs, dpADCs), mRNA, and recombinant proteins, supported by three Shanghai facilities (Zhangjiang CBTI, Jinshan, and Fengxian) compliant with NMPA, FDA, and EMA standards.

Product and service16 records
1AmigoCHO Cell Line Development Platform
CategoryCell Line Development Platform
Description

Proprietary cell line development platform supporting high-titer, high-quality, and stable clone development including cell pool establishment, expansion, clone selection, and stability analysis for monoclonal antibodies, bispecific antibodies, ADCs, enzymes, and fusion proteins. Achieves 8 g/L expression levels and 7-week timelines.

2Conjugation Toolbox
CategoryConjugation Technology Platform
Description

Modular technology platform for rapid development and optimization of diverse bioconjugate modalities (ADCs, RDCs, AOCs, APCs, bispecific ADCs, dual-payload ADCs) supporting both random and site-specific conjugation technologies including cysteine-, lysine-, engineered cysteine-, interchain cysteine re-bridging-, enzymatic (mTG, sortase)-, and glyco-remodeling-based (GlycoConnect, GlycoT, DisacLink, iGDC) approaches.

3IMPACT Drug Product Development Platform
CategoryDrug Product Development Platform
Description

Indication-, Molecule-, and Phase-Accountable drug product development platform delivering formulation and process solutions for complex and high-potency biologics across liquid, lyophilized, high-concentration, and multi-dose presentations.

4Payload-Linker CMC Development Platform
CategoryPayload-Linker CMC Platform
Description

CMC development platform offering multiple payload options (Auristatin, Maytansine, Camptothecin, Eribulin, PBD dimer, macrocyclic molecular glue, E3 ligase ligand) and linker options (peptide, PEG, sugar linkers), supporting ADC and bioconjugate CMC development.

5Comprehensive Analytical Platform
CategoryAnalytical Platform
Description

Integrated analytical platform comprising a Physicochemical Platform, Mass Spectrometry Platform, and Bioassay Platform for efficient analytical method development and in-depth product characterization covering critical quality attributes across the product lifecycle.

6Upstream Process Development Platform
CategoryUpstream Process Development Platform
Description

Process optimization, scale-up, and characterization platform supporting workflows from preclinical material preparation and IND/BLA-enabling process development through technology transfer and scale-up, with project timelines shortenable to as little as 9 weeks.

7Downstream Process Development Platform
CategoryDownstream Process Development Platform
Description

Downstream process development platform supporting chromatography process development, filtration process development, tech transfer and scale-up, and process characterization to shorten timelines while improving purity, reducing impurities, and increasing yield.

8Developability Assessment
CategoryCDMO Service
Description

Service bridging late-stage discovery with early CMC development for candidate drug preparation and developability assessment, integrating cloning/expression/purification/conjugation processes for drug substance manufacturing.

9Antibodies & Recombinant Biotherapeutics CDMO Services
CategoryCDMO Service - Biologics
Description

End-to-end CDMO services covering cell line construction, upstream/downstream process development, drug substance and drug product manufacturing, and release testing for monoclonal antibodies, bispecific antibodies, and fusion proteins.

10Bioconjugates CDMO Services
CategoryCDMO Service - Bioconjugates
Description

Comprehensive bioconjugate services including payload-linker CMC, antibody intermediate manufacturing, bioconjugate process development, drug substance/product manufacturing, and release testing for ADCs, RDCs, AOCs, PDCs, and other novel drug conjugates.

11mRNA CDMO Services
CategoryCDMO Service - mRNA
Description

Full mRNA CDMO services including plasmid linearization process development, in vitro mRNA transcription, mRNA-LNP process development, mRNA production, and mRNA release testing.

12Analytical Science & Quality Control Services
CategoryAnalytical Service
Description

Physicochemical analysis of recombinant biotherapeutics and bioconjugates, mass spectrometry analysis, bioassay development, release testing, and stability studies.

13Regulatory Affairs Services
CategoryRegulatory Affairs Service
Description

Comprehensive CMC dossier templates, regulatory guideline interpretation, and CMC knowledge sharing with experience in biologics IND, BLA, and NDA applications.

14Shanghai Fengxian Commercial Production Base
CategoryManufacturing Facility
Description

130,000+ square meter smart manufacturing facility offering 66,000L of drug substance capacity (Phase IA) and up to two million vials annually (Phase IB), compliant with NMPA, FDA, and EMA standards for antibodies, ADCs, NDCs, and recombinant proteins.

15Jinshan Manufacturing Site
16Zhangjiang Center of Biological Technology and Innovation (CBTI)
CategoryR&D Center
Description

Technology-driven central R&D center focusing on early R&D and process development for antibodies, proteins, novel drug conjugates, and advanced therapies, building and optimizing the technology platforms for cell line development, process development, conjugation toolbox, and analytical method development.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-31
Description

Strategic partnership for novel drug conjugate (NDC) CMC development. AsymBio served as strategic partner supporting CMC studies for IND submission of Betabart (RV-01), a Lu177-B7H3 radiopharmaceutical. FDA IND approval achieved in 2025.

2T-E Meds
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic cooperation agreement signed to drive innovation in drug conjugates and explore the future of targeted therapeutics. Partnership marks beginning of deep collaboration in targeted therapeutics development.

asymbio.com
Strategic tierCoreTypeTechnology or Integration
Description

Technology partnership for GlycoConnect glyco-remodeling conjugation technology. AsymBio has established CMC development expertise with GlycoConnect technology for site-specific ADC conjugation.

4Asymchem Group
Strategic tierCoreTypeOthers
Description

Parent company and strategic business unit of Asymchem Group (stock codes: 002821.SZ / 6821.HK). AsymBio integrates with Group resources including Tianjin payload-linker R&D and manufacturing facilities.

asymbio.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Korean biopharmaceutical company with biologics manufacturing capabilities for biosimilars and innovative biologics. Comparable as a regional player in Asia-Pacific biologics manufacturing with overlapping capabilities.

TypeDirect peer
Description

Chinese biopharmaceutical company with growing biologics CDMO services supporting antibody and recombinant protein development and manufacturing. Comparable to AsymBio as a China-headquartered biologics CDMO.

TypeBroad incumbent
Description

Major global CDMO with biologics, ADC, and drug product capabilities across fill-finish and commercial manufacturing. Comparable as a broad incumbent offering biologics CDMO services to pharma and biotech clients.

TypeBroad incumbent
Description

Global leader in biologics CDMO with deep expertise in mammalian cell culture, ADCs (via acquired Synaffix platform, which AsymBio partners with), and commercial-scale manufacturing. Comparable as a global incumbent offering overlapping capabilities, though broader in scope than AsymBio's biologics focus.

TypeDirect peer
Description

Largest China-based biologics CDMO offering end-to-end antibody, recombinant protein, ADC, and bioconjugate development and manufacturing services globally. Directly comparable to AsymBio across biologics modalities, customer base (global pharma/biotech), and integrated one-stop CDMO model.

TypeDirect peer
Description

Global contract development and manufacturing organization specializing in mammalian and microbial biologics, with capabilities spanning cell line development through commercial manufacturing. Comparable to AsymBio as a similarly scaled CDMO focused on biologics.

TypeDirect peer
Description

China-rooted life sciences company with biopharmaceutical CDMO services (Bestzyme, GenScript ProBio) offering biologics development and manufacturing. Comparable as a Chinese-based biologics CDMO serving global biotech clients.

TypeBroad incumbent
Description

Korean global biologics CDMO with very large-scale commercial manufacturing capacity and broad service offerings from cell line to commercial supply. Comparable as an established incumbent in biologics CDMO serving global pharma clients.

TypeBroad incumbent
Description

China-rooted global CRO/CDMO with growing biologics CDMO capabilities alongside established small-molecule services. Comparable as a parent-affiliated biopharmaceutical services platform with overlapping biologics offerings and Asymchem Group's broader competitive set.

10Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Global biologics CDMO division of Boehringer Ingelheim offering mammalian cell culture, microbial, and bioconjugate manufacturing. Comparable as an established global CDMO serving pharma clients with biologics outsourcing needs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AsymBio

Biologics Contract Development and Manufacturing (CDMO) Servicesasymbio.com

AsymBio is a biopharmaceutical CDMO and subsidiary of Asymchem Group providing end-to-end biologics development and manufacturing services (antibodies, recombinant proteins, ADCs, novel drug conjugates, mRNA) for global pharma and biotech clients across a Shanghai-based three-facility manufacturing network compliant with NMPA, FDA, and EMA standards.

What AsymBio does

AsymBio (凯莱英生物技术有限公司) is a biopharmaceutical contract development and manufacturing organization (CDMO) and wholly-owned subsidiary of Asymchem Group (002821.SZ / 6821.HK), founded in January 2019. The company provides end-to-end CDMO services across the full biopharmaceutical development lifecycle for global pharmaceutical and biotech clients, spanning early-stage research, process development, toxicology and clinical batches, and commercial-scale manufacturing for biologics including monoclonal antibodies, bispecific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), novel drug conjugates (RDCs, AOCs, PDCs, APCs, bispecific ADCs, dual-payload ADCs), and mRNA therapeutics.

The company's core technology consists of seven integrated platforms: the proprietary AmigoCHO Cell Line Development Platform achieving 8 g/L expression levels in 7 weeks; Upstream and Downstream Process Development Platforms with upstream timelines shortened to 9 weeks; the Conjugation Toolbox supporting multiple conjugation modalities (cysteine, lysine, engineered cysteine, interchain bridging, enzymatic via mTG/sortase, and glyco-remodeling via GlycoConnect, GlycoT, DisacLink, iGDC); the IMPACT Drug Product Development Platform; the Payload-Linker CMC Development Platform supporting 70+ IND and 13 NDA projects; and a Comprehensive Analytical Platform integrating physicochemical, mass spectrometry, and bioassay capabilities. Operations are conducted across a Shanghai "Golden Triangle" network: the Zhangjiang Center of Biological Technology and Innovation (CBTI), the Jinshan manufacturing site, and the 130,000+ square meter Fengxian Commercial Production Base (66,000L bioreactor capacity, 2 million vial annual capacity), with a US business development office in Woburn, MA. Facilities are compliant with NMPA, FDA, and EMA standards.

AsymBio operates a project-based B2B contract services revenue model with pricing specific to each engagement. Go-to-market is event-driven enterprise field sales, with active participation in major industry conferences (World ADC, BIOCHINA, Festival of Biologics, ADC Asia Congress) and direct engagement through a business development team. Customer concentration is horizontal across pharmaceutical and biotech companies globally, with the company leveraging the Asymchem Group ecosystem including Tianjin's payload-linker manufacturing capabilities for integrated supply chain advantages.

AsymBio firmographics

Firmographics
Name
AsymBio
Legal name
凯莱英生物技术有限公司
Website
https://asymbio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
AsymBio is a biopharmaceutical CDMO and subsidiary of Asymchem Group providing end-to-end biologics development and manufacturing services (antibodies, recombinant proteins, ADCs, novel drug conjugates, mRNA) for global pharma and biotech clients across a Shanghai-based three-facility manufacturing network compliant with NMPA, FDA, and EMA standards.
Ownership category
akta.pro rank

AsymBio industry classification

Industry
Product category
Biologics Contract Development and Manufacturing (CDMO) Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biologics CDMO services
  • Antibody manufacturing
  • Drug conjugate development
  • Recombinant protein production
  • Biopharmaceutical contract manufacturing

Where AsymBio is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices5 records

Markets served

AsymBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Biopharmaceutical CDMO Services: Full-service contract development and manufacturing organization providing one-stop CDMO solutions for biologics including antibodies, recombinant proteins, and novel drug conjugates. Services span early-stage research, process development, toxicology batches, clinical batches, and commercial-scale manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

AsymBio product offering

Product offering

Core offering

AsymBio provides one-stop biologics contract development and manufacturing organization (CDMO) services for global pharmaceutical and biotech companies, spanning the full biopharmaceutical lifecycle from cell line development, upstream and downstream process development, conjugation, drug product development, and analytical services through to clinical and commercial-scale manufacturing for antibodies, recombinant proteins, novel drug conjugates (ADCs, RDCs, AOCs, PDCs, BsADCs), and mRNA products.

Product overview

AsymBio is a technology-driven biologics CDMO and subsidiary of Asymchem Group providing integrated one-stop CDMO services spanning the full biopharmaceutical development lifecycle. The company operates seven integrated technology platforms: AmigoCHO Cell Line Development Platform for high-titer clone development; Upstream and Downstream Process Development Platforms for IND-enabling workflows; Conjugation Toolbox for ADC and bioconjugate process development supporting random and site-specific conjugation technologies; IMPACT Drug Product Development Platform for formulation solutions; Payload-Linker CMC Development Platform supporting 70+ IND and 13 NDA projects; and Comprehensive Analytical Platform for physicochemical, mass spectrometry, and bioassay characterization. The company provides end-to-end services from early-stage research through commercial-scale manufacturing across antibodies, ADCs, novel drug conjugates (RDCs, AOCs, PDCs, APCs, BsADCs, dpADCs), mRNA, and recombinant proteins, supported by three Shanghai facilities (Zhangjiang CBTI, Jinshan, and Fengxian) compliant with NMPA, FDA, and EMA standards.

Differentiator

Problem solved

Functional benefit

Products and services

  • AmigoCHO Cell Line Development Platform Proprietary cell line development platform supporting high-titer, high-quality, and stable clone development including cell pool establishment, expansion, clone selection, and stability analysis for monoclonal antibodies, bispecific antibodies, ADCs, enzymes, and fusion proteins. Achieves 8 g/L expression levels and 7-week timelines.
  • Conjugation Toolbox Modular technology platform for rapid development and optimization of diverse bioconjugate modalities (ADCs, RDCs, AOCs, APCs, bispecific ADCs, dual-payload ADCs) supporting both random and site-specific conjugation technologies including cysteine-, lysine-, engineered cysteine-, interchain cysteine re-bridging-, enzymatic (mTG, sortase)-, and glyco-remodeling-based (GlycoConnect, GlycoT, DisacLink, iGDC) approaches.
  • IMPACT Drug Product Development Platform Indication-, Molecule-, and Phase-Accountable drug product development platform delivering formulation and process solutions for complex and high-potency biologics across liquid, lyophilized, high-concentration, and multi-dose presentations.
  • Payload-Linker CMC Development Platform CMC development platform offering multiple payload options (Auristatin, Maytansine, Camptothecin, Eribulin, PBD dimer, macrocyclic molecular glue, E3 ligase ligand) and linker options (peptide, PEG, sugar linkers), supporting ADC and bioconjugate CMC development.
  • Comprehensive Analytical Platform Integrated analytical platform comprising a Physicochemical Platform, Mass Spectrometry Platform, and Bioassay Platform for efficient analytical method development and in-depth product characterization covering critical quality attributes across the product lifecycle.
  • Upstream Process Development Platform Process optimization, scale-up, and characterization platform supporting workflows from preclinical material preparation and IND/BLA-enabling process development through technology transfer and scale-up, with project timelines shortenable to as little as 9 weeks.
  • Downstream Process Development Platform Downstream process development platform supporting chromatography process development, filtration process development, tech transfer and scale-up, and process characterization to shorten timelines while improving purity, reducing impurities, and increasing yield.
  • Developability Assessment Service bridging late-stage discovery with early CMC development for candidate drug preparation and developability assessment, integrating cloning/expression/purification/conjugation processes for drug substance manufacturing.
  • Antibodies & Recombinant Biotherapeutics CDMO Services End-to-end CDMO services covering cell line construction, upstream/downstream process development, drug substance and drug product manufacturing, and release testing for monoclonal antibodies, bispecific antibodies, and fusion proteins.
  • Bioconjugates CDMO Services Comprehensive bioconjugate services including payload-linker CMC, antibody intermediate manufacturing, bioconjugate process development, drug substance/product manufacturing, and release testing for ADCs, RDCs, AOCs, PDCs, and other novel drug conjugates.
  • mRNA CDMO Services Full mRNA CDMO services including plasmid linearization process development, in vitro mRNA transcription, mRNA-LNP process development, mRNA production, and mRNA release testing.
  • Analytical Science & Quality Control Services Physicochemical analysis of recombinant biotherapeutics and bioconjugates, mass spectrometry analysis, bioassay development, release testing, and stability studies.
  • Regulatory Affairs Services Comprehensive CMC dossier templates, regulatory guideline interpretation, and CMC knowledge sharing with experience in biologics IND, BLA, and NDA applications.
  • Shanghai Fengxian Commercial Production Base 130,000+ square meter smart manufacturing facility offering 66,000L of drug substance capacity (Phase IA) and up to two million vials annually (Phase IB), compliant with NMPA, FDA, and EMA standards for antibodies, ADCs, NDCs, and recombinant proteins.
  • Jinshan Manufacturing Site
  • Zhangjiang Center of Biological Technology and Innovation (CBTI) Technology-driven central R&D center focusing on early R&D and process development for antibodies, proteins, novel drug conjugates, and advanced therapies, building and optimizing the technology platforms for cell line development, process development, conjugation toolbox, and analytical method development.

Quantifiable outcome

  • IND-enabling conjugation process development can be completed in 2-3 months
  • +5 more outcomes

Companies that use AsymBio

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

AsymBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

AsymBio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Radiopharm TheranosticscoreStrategic or Co-development Partner · 31 July 2025Strategic partnership for novel drug conjugate (NDC) CMC development. AsymBio served as strategic partner supporting CMC studies for IND submission of Betabart (RV-01), a Lu177-B7H3 radiopharmaceutical. FDA IND approval achieved in 2025.
  • T-E MedscoreStrategic or Co-development PartnerStrategic cooperation agreement signed to drive innovation in drug conjugates and explore the future of targeted therapeutics. Partnership marks beginning of deep collaboration in targeted therapeutics development.
  • Synaffix (now Lonza)coreTechnology or IntegrationTechnology partnership for GlycoConnect glyco-remodeling conjugation technology. AsymBio has established CMC development expertise with GlycoConnect technology for site-specific ADC conjugation.
  • Asymchem GroupcoreOthersParent company and strategic business unit of Asymchem Group (stock codes: 002821.SZ / 6821.HK). AsymBio integrates with Group resources including Tianjin payload-linker R&D and manufacturing facilities.

Scale indicators12 records

Recent moves9 records

Expansion highlights5 records

AsymBio competitors and assessment

Company assessment

Regional players

  • Celltrion: Korean biopharmaceutical company with biologics manufacturing capabilities for biosimilars and innovative biologics. Comparable as a regional player in Asia-Pacific biologics manufacturing with overlapping capabilities.

Direct peers

  • Mabwell: Chinese biopharmaceutical company with growing biologics CDMO services supporting antibody and recombinant protein development and manufacturing. Comparable to AsymBio as a China-headquartered biologics CDMO.
  • WuXi Biologics: Largest China-based biologics CDMO offering end-to-end antibody, recombinant protein, ADC, and bioconjugate development and manufacturing services globally. Directly comparable to AsymBio across biologics modalities, customer base (global pharma/biotech), and integrated one-stop CDMO model.
  • AGC Biologics: Global contract development and manufacturing organization specializing in mammalian and microbial biologics, with capabilities spanning cell line development through commercial manufacturing. Comparable to AsymBio as a similarly scaled CDMO focused on biologics.
  • Genscript Biotech: China-rooted life sciences company with biopharmaceutical CDMO services (Bestzyme, GenScript ProBio) offering biologics development and manufacturing. Comparable as a Chinese-based biologics CDMO serving global biotech clients.

Broad incumbents

  • Catalent: Major global CDMO with biologics, ADC, and drug product capabilities across fill-finish and commercial manufacturing. Comparable as a broad incumbent offering biologics CDMO services to pharma and biotech clients.
  • Lonza Group: Global leader in biologics CDMO with deep expertise in mammalian cell culture, ADCs (via acquired Synaffix platform, which AsymBio partners with), and commercial-scale manufacturing. Comparable as a global incumbent offering overlapping capabilities, though broader in scope than AsymBio's biologics focus.
  • Samsung Biologics: Korean global biologics CDMO with very large-scale commercial manufacturing capacity and broad service offerings from cell line to commercial supply. Comparable as an established incumbent in biologics CDMO serving global pharma clients.
  • Pharmaron: China-rooted global CRO/CDMO with growing biologics CDMO capabilities alongside established small-molecule services. Comparable as a parent-affiliated biopharmaceutical services platform with overlapping biologics offerings and Asymchem Group's broader competitive set.
  • Boehringer Ingelheim BioXcellence: Global biologics CDMO division of Boehringer Ingelheim offering mammalian cell culture, microbial, and bioconjugate manufacturing. Comparable as an established global CDMO serving pharma clients with biologics outsourcing needs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

AsymBio social profiles

Digital presence

AsymBio compliance and trust

Trust signal

Compliance5 records

AsymBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AsymBio leadership team

Management profile

Number of profiles

Profiles12 records

AsymBio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AsymBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AsymBio

What does AsymBio do?

AsymBio provides one-stop biologics contract development and manufacturing organization (CDMO) services for global pharmaceutical and biotech companies, spanning the full biopharmaceutical lifecycle from cell line development, upstream and downstream process development, conjugation, drug product development, and analytical services through to clinical and commercial-scale manufacturing for antibodies, recombinant proteins, novel drug conjugates (ADCs, RDCs, AOCs, PDCs, BsADCs), and mRNA products.

Is AsymBio a public or private company?

AsymBio is a private company. It is classified as corporate owned and is currently operating.

When was AsymBio founded?

AsymBio was founded in 2019. It employs 11 to 50 people.

Where is AsymBio based?

AsymBio is headquartered in Shanghai, China, in the Asia region.

How does AsymBio make money?

One revenue line is on record: biopharmaceutical CDMO Services.

Who are AsymBio's main competitors?

Celltrion is listed as a regional player. Direct peers are Mabwell, WuXi Biologics, AGC Biologics and Genscript Biotech. Broad incumbents are Catalent, Lonza Group, Samsung Biologics, Pharmaron and Boehringer Ingelheim BioXcellence.

Does AsymBio have an API?

No public API is recorded for AsymBio.

What industry is AsymBio in?

AsymBio's product category is Biologics Contract Development and Manufacturing (CDMO) Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Genengnews10 CDMO Up & Comers 2026Ten CDMOs are listed as up-and-comers for 2026, including Artis BioSolutions, AsymBio, and Bora Group, with actions such as acquisitions, contracts, and facility openings. Bora Group completed a $127.5 million acquisition of MacroGenics and signed a $250 million GSK contract, while Resilience expanded its Eli Lilly partnership with a $750 million expansion.YahooAsymBio to secure $184m to support growth in biologics manufacturingBiologics CDMO AsymBio is set to secure approximately $184 million (1.2397 billion yuan) from Asymchem Group, Hillhouse Qirui, and other investors to support its growth and manufacturing capacity expansion. Asymchem Group will contribute 1.05 billion yuan while Hillhouse Qirui will invest 177 million yuan, with Asymchem Group's shareholding in AsymBio rising to 83.4965% following the transaction. The funding will support R&D capabilities, GMP manufacturing lines, and high-containment facilities, with AsymBio reporting 470 million yuan in 2025 revenue and over 140 million yuan in Q1 2026 revenue.Pharmaceutical TechnologyAsymBio to secure $184m to support growth in biologics manufacturingAsymBio, a biologics contract development and manufacturing organization (CDMO), is set to secure approximately $184 million (1.2397bn yuan) from Asymchem Group, Hillhouse Qirui, and other investors to support its long-term growth and expansion. Asymchem Group will contribute 1.05bn yuan while Hillhouse Qirui will invest 177m yuan, with Asymchem Group's shareholding in AsymBio set to rise to 83.4965% following the transaction. The funding will support expansion of R&D capabilities, GMP manufacturing lines, and high-containment facilities, with AsymBio reporting 470m yuan in revenue for 2025 and exceeding 140m yuan in Q1 2026.BingxAsymBio Raises RMB 1.2397 Billion (US$184 Million) in Capital Increase, Asymchem Stake Rises to 83.4965%Asymchem and external investors injected RMB 1.2397bn (US$184m) into biologics CDMO AsymBio, raising Asymchem's stake to 83.4965%. The funding supports capacity expansion and platform investment amid rising demand for outsourced manufacturing of complex biologics.Third NewsAsymBio's Recent Capital Infusion of $184 Million Sets the Stage for Future GrowthAsymBio, a Contract Development and Manufacturing Organization (CDMO) specializing in biologics, announced on August 4, 2026, a capital infusion of approximately $184 million (RMB 1.2397 billion) from a consortium including Asymchem Group and Hillhouse Qirui. Asymchem Group will increase its ownership stake in AsymBio to 83.4965% as part of the investment, with Hillhouse Qirui contributing approximately $26 million. The funds will be allocated to expanding R&D platforms and GMP facilities for high-potency biologics manufacturing, including antibody-drug conjugates and bispecific antibodies.BitlyAsymBio Secures US$184 Million Capital Injection to Support Long-Term GrowthAsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and subsidiary of Asymchem Group, has secured a total capital injection of RMB 1.2397 billion (approximately US$184 million) from Asymchem Group and Hillhouse Qirui. Following this transaction, Asymchem Group's ownership stake in AsymBio will increase to approximately 83.5%. The funding will support AsymBio's capacity expansion and operational scaling as the company pursues profitability, having generated approximately US$70 million in 2025 revenue with continued growth momentum into 2026.YahooAsymBio Secures US$184 Million Capital Injection to Support Long-Term GrowthAsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and subsidiary of Asymchem Group, announced a capital injection of RMB 1.2397 billion (approximately US$184 million) from Asymchem Group and Hillhouse Qirui, with Asymchem Group contributing RMB 1.05 billion to increase its stake to 83.4965%. The new capital will support capacity ramp-up, scaled delivery of client programs, and the company's path toward profitability, with the investment reflecting confidence in AsymBio's differentiated CDMO strategy for complex biologics including ADCs and NDCs. The company reported 2025 revenue of approximately RMB 470 million (US$70 million) and Q1 2026 revenue exceeding RMB 140 million (US$21 million), indicating strong growth momentum in the biologics outsourcing sector.PR Newswire APACAsymBio Secures US$184 Million Capital Injection to Support Long-Term GrowthAsymBio, a biologics-focused Contract Development and Manufacturing Organization and subsidiary of Asymchem Group, has secured a capital injection of approximately US$184 million (RMB 1.2397 billion) from Asymchem Group and Hillhouse Qirui. Asymchem Group contributed approximately US$156 million while Hillhouse Qirui contributed approximately US$26 million, with Asymchem Group's stake in AsymBio increasing to 83.4965% upon completion. The funding will support capacity expansion and scaled delivery of client programs as AsymBio pursues profitability, with the company reporting 2025 revenue of approximately US$70 million and Q1 2026 revenue exceeding US$21 million.PR NewswireAsymBio Secures US$184 Million Capital Injection to Support Long-Term GrowthAsymBio, a biologics-focused Contract Development and Manufacturing Organization and subsidiary of Asymchem Group, has secured a capital injection of RMB 1.2397 billion (approximately US$184 million) from Asymchem Group, Hillhouse Qirui, and other investors. Upon completion, Asymchem Group's stake in AsymBio will rise to 83.4965%, with Asymchem Group contributing approximately US$156 million and Hillhouse Qirui approximately US$26 million. The capital will fund capacity ramp-up, R&D platforms, and GMP manufacturing facilities to support the company's one-stop end-to-end CDMO strategy for complex biologics including ADCs, NDCs, and bispecific antibodies, as the company targets improved operating leverage and a path toward profitability.Life Science Company NewsChina's AsymBio secures $184 M capital injection to support long-term growthAsymBio received a total capital injection of RMB 1.2397 billion ($184 million) from Asymchem Group, Hillhouse Qirui, and other investors. Asymchem's stake rose to 83.4965%, with Asymchem contributing RMB 1.05 billion and Hillhouse RMB 177 million. The company reported RMB 470 million revenue in 2025 and over RMB 140 million in Q1 2026.